TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections. Continue reading New Drug to Help with Resistant Fungal Lung Infections
Pulmatrix, Inc. (NASDAQ: PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to the lungs to fight Continue reading Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article
Drug Resistance Updates, 08/28/2015Verweij PE, et al.
Intravenous therapy with either micafungin or L–AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary Continue reading International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus